At ResMed, we’re focused on improving patient compliance and providing comfortable, effective therapy. That’s why we continue to develop ventilators around iVAPS algorithms, an innovative technology that adapts to patients, especially those with Chronic Obstructive Pulmonary Disease (COPD). Learn more about COPD.
By targeting alveolar ventilation, iVAPS continually maintains ventilation according to the patient’s metabolic needs, decreasing the risk of over and under-ventilation with changing respiratory rate. Data from extensive bench testing against VAPS ventilators and clinical trials have shown that iVAPS effectively meets patients’ ventilatory needs. It also responds faster to respiratory changes without compromising patient comfort or sleep quality.
Volume assured pressure support (iVAPS) ventilators combine the advantages of pressure-support ventilation, such as patient comfort and patient-ventilator synchrony, with the assurance of a tidal volume target. However, while this enables VAPS modes to meet ventilatory needs, response to respiratory changes is slow. Another limitation of VAPS modes is the enforcement of a mandatory target tidal volume on every breath. Changes in breath rate will still trigger the same tidal volume to be delivered with each breath, which can lead to patient discomfort and sleep disruption.
Several clinical trials have been conducted to evaluate the iVAPS algorithm compared with the standard pressure-support ventilation (PSV) in different patient populations. Numerous studies have shown iVAPS to be as effective as PSV for the long-term management of ventilatory failure in stable COPD patients.1,2,3,4